EGFR T790M/L858R-IN-9 

EGFR T790M/L858R-IN-9 (Compound 8) is an EGFR-L858R/T790M inhibitor that demonstrates potent inhibitory phosphorylation effects against the EGFR-L858R/T790M mutant kinase, with an IC⁵⁰ value of 0.0064µM. EGFR T790M/L858R-IN-9 also inhibits the proliferation of non-small cell lung cancer (NSCLC) cells and can be utilized in cancer research^[1].

IC50: 0.0064 μM (EGFRT-790M/L858R)^[1].

EGFR T790M/L858R-IN-9 (Compound 8) exhibits antiproliferative activity in both mutant and wild-type NSCLC cell lines, with IC⁵⁰ values of 0.170 μM (for proliferation of H1975 cells harboring the EGFR-L858R/T790M mutation) and 0.554 μM (for A549 cells), respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

517.60

C₂₆H₂₇N₇O₃S

COC1=CC=C(C2=NN=C(NC3=NC(OC4=CC(N5CCN(C(CC)=O)CC5)=CC=C4)=NC=C3)S2)C=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ahmad I, et al. Design, Synthesis, and Evaluation of Novel 2, 4‐disubstituted Pyrimidine Derivatives as Double Mutant Epidermal Growth Factor Receptor‐L858R/T790M Tyrosine Kinase Inhibitors[J]. Journal of Biochemical and Molecular Toxicology, 2025, 39(1): e70077.